CanSino Biologics' (HKG:6185, SHA:688185) attributable loss narrowed to 378.9 million yuan in 2024 from 1.48 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the vaccine manufacturer narrowed to 1.53 yuan from 6.01 yuan in the previous year.
Revenue surged 137% to 846.3 million yuan from 357.1 million yuan a year earlier.